OBJECTIVES: To report outcomes of oral cavity cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy (chemoIMRT). METHODS: Between 2001 and 2004, 21 patients with oral cavity squamous cell carcinoma underwent definitive chemoIMRT. Sites included were oral tongue (n = 9), floor of mouth (n = 6), buccal mucosa (n = 3), retromolar trigone (n = 2), and hard palate (n = 1). Most had stage III-IV disease (n = 20). The most common regimen was 5 days infusional 5-fluorouracil (600 mg/m(2)/d × 5 days), hydroxyurea (500 mg, PO BID), and 1.5 Gy twice-daily irradiation to 72 to 75 Gy. RESULTS: The median follow-up for surviving patients was 60 months. Treatment failure occurred as follows: local-1, regional-1, and distant metastases-2. The 2- and 5-year estimates of locoregional progression-free survival, disease-free survival, and overall survival were 90% and 90%, 71% and 71%, and 76% and 76%, respectively. Late complications included osteoradionecrosis (3 patients, 14%). CONCLUSIONS: Concurrent chemoIMRT results in promising locoregional control for oral cavity squamous cell carcinomas with acceptable toxicity.
OBJECTIVES: To report outcomes of oral cavity cancerpatients treated with concurrent chemotherapy and intensity-modulated radiotherapy (chemoIMRT). METHODS: Between 2001 and 2004, 21 patients with oral cavity squamous cell carcinoma underwent definitive chemoIMRT. Sites included were oral tongue (n = 9), floor of mouth (n = 6), buccal mucosa (n = 3), retromolar trigone (n = 2), and hard palate (n = 1). Most had stage III-IV disease (n = 20). The most common regimen was 5 days infusional 5-fluorouracil (600 mg/m(2)/d × 5 days), hydroxyurea (500 mg, PO BID), and 1.5 Gy twice-daily irradiation to 72 to 75 Gy. RESULTS: The median follow-up for surviving patients was 60 months. Treatment failure occurred as follows: local-1, regional-1, and distant metastases-2. The 2- and 5-year estimates of locoregional progression-free survival, disease-free survival, and overall survival were 90% and 90%, 71% and 71%, and 76% and 76%, respectively. Late complications included osteoradionecrosis (3 patients, 14%). CONCLUSIONS: Concurrent chemoIMRT results in promising locoregional control for oral cavity squamous cell carcinomas with acceptable toxicity.
Authors: Michael T Spiotto; Gina Jefferson; Barry Wenig; Michael Markiewicz; Ralph R Weichselbaum; Matthew Koshy Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-07-01 Impact factor: 6.223
Authors: Eli D Scher; Paul B Romesser; Christine Chen; Felix Ho; Yen Wuu; Eric J Sherman; Matthew G Fury; Richard J Wong; Sean McBride; Nancy Y Lee; Nadeem Riaz Journal: Oral Oncol Date: 2015-05-07 Impact factor: 5.337
Authors: Steven B Chinn; Matthew E Spector; Emily L Bellile; Laura S Rozek; Tasha Lin; Theodoros N Teknos; Mark E Prince; Carol R Bradford; Susan G Urba; Thomas E Carey; Avraham Eisbruch; Gregory T Wolf; Francis P Worden; Douglas B Chepeha Journal: JAMA Otolaryngol Head Neck Surg Date: 2014-02 Impact factor: 6.223
Authors: Kristin Lang; Melissa Baur; Thomas Held; Rami El Shafie; Julius Moratin; Christian Freudlsperger; Karim Zaoui; Nina Bougatf; Jürgen Hoffmann; Peter K Plinkert; Jürgen Debus; Sebastian Adeberg Journal: Radiol Oncol Date: 2021-11-19 Impact factor: 2.991